Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HSCT for refractory autoimmune disorders
ACTRN12613000339752Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Mar 2011
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous hematopoietic stem cells, cyclophosphamide, antithymocyte globulin, carmustine, cytarabine and 2 more in autoimmune disease, systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and 4 more (2 arms), sponsored by St Vincent's Hospital. Primary endpoints: Transplant-related mortality by day 100 and Disease-specific efficacy of HSCT. Started Mar 2011; status: recruiting.
02
Drugs
autologous hematopoietic stem cellscyclophosphamideantithymocyte globulincarmustinecytarabine
03
Conditions
autoimmune diseasesystemic sclerosis (SSc)systemic lupus erythematosus (SLE)multiple sclerosis (MS)vasculitis
Beyond the preview
Go deeper on ACTRN12613000339752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000339752.